GPER1 and neoplasm: The small-molecule targeted agonist of GPER, LNS8801, has demonstrated impressive results in a multicenter Phase 1–2A clinical trial, exhibiting encouraging anti-tumor effects in patients with metastatic uveal melanoma, whether used alone or in combination with pembrolizumab.